ESR1 and neoplasm: Indeed, Gates et al. have previously reported pharmacological inhibition of AIB1 with a small molecule inhibitor SI-2 alone may be enough to re-sensitize resistant tumor to endocrine treatment in ESR1 mutant tumors in vivo [18].